COCRYSTAL PHARMA, INC. Deferred Federal Income Tax Expense (Benefit)
COCRYSTAL PHARMA, INC. (COCP) reported Deferred Federal Income Tax Expense (Benefit) of -$10.35 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-27.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2020-03-27
- COCRYSTAL PHARMA, INC. deferred federal income tax expense (benefit) for fiscal 2018 was -$10.35M.
- COCRYSTAL PHARMA, INC. deferred federal income tax expense (benefit) for fiscal 2017 was -$6.88M.
- COCRYSTAL PHARMA, INC. deferred federal income tax expense (benefit) for fiscal 2016 was -$32.42M.
- COCRYSTAL PHARMA, INC. deferred federal income tax expense (benefit) for fiscal 2015 was -$12.00M.
| Period end | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|
| 2018-12-31 | -$10.35M 10-K · filed 2020-03-27 |
| 2017-12-31 | -$6.88M 10-K · filed 2019-04-01 |
| 2016-12-31 | -$32.42M 10-K · filed 2018-03-21 |
| 2015-12-31 | -$12.00M 10-K · filed 2018-03-21 |
| 2014-12-31 | -$51.00K 10-K · filed 2017-03-31 |
| 2013-12-31 | -$1.19M 10-K · filed 2014-03-31 |
| 2012-12-31 | -$894.13K 10-K · filed 2014-03-31 |
| 2011-12-31 | -$1.69M 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |